Pfizer, Lilly to mull anti-NGF mAb's future after joint safety events spike in long-term readout

With the latest Phase III data for Pfizer and Lilly's tanezumab showing a long-term increase in the incidence of a safety concern that has dogged the anti-NGF mAb, the partners said late Thursday they now plan to review the totality of data from the tanezumab program with regulatory authorities to determine next steps.

High-dose tanezumab from Pfizer Inc. (NYSE:PFE) and

Read the full 594 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE